Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy
compared with observation in triple negative breast cancer (TNBC) patients with residual
invasive disease after platinum and taxanes based neoadjuvant chemotherapy.